查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1767752

全球感染疾病體外診斷市場按產品類型、最終用戶、地區、產業分析、規模、佔有率、成長、趨勢和預測（2025-2032 年）

Infectious Disease In-vitro Diagnostics Market by Product Type, End-Users, and Geography: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
出版日期: | 出版商: Persistence Market Research | 英文 188 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

主要發現

  • 感染疾病IVD市場規模（2025年）：466億美元
  • 預計市場價值（2032年）：641億美元
  • 全球市場成長率：4.7%（2025年至2032年的複合年成長率）

感染疾病體外診斷市場 - 報告範圍

感染疾病體外診斷在快速準確地檢測導致愛滋病毒、肝炎、流感、結核病和 SARS-CoV-2 等新興病毒威脅的感染疾病方面發揮著至關重要的作用。這些診斷技術包括分子檢測、免疫測定和就地檢驗技術，有助於早期診斷、指導治療決策並促進感染控制工作。感染疾病體外診斷市場面向醫院、臨床實驗室、診斷中心和照護現場，提供各種檢測套組、試劑、儀器和軟體解決方案。市場成長的驅動力包括感染疾病的流行、對快速準確檢測日益成長的需求，以及診斷平台的技術進步，從而提高了靈敏度、特異性和周轉時間。

市場成長動力

全球感染疾病診斷 (IVD) 市場受到多種因素驅動，例如全球感染疾病病率的上升、人們對早期發現和疾病控制意識的不斷增強。抗生素抗藥性感染疾病的增加、疫情爆發時對精準診斷的需求以及政府對感染疾病監測和篩檢的強力支持，進一步推動了市場的成長。分子診斷技術的進步，例如次世代定序和多重 PCR，使得同時檢測多種病原體成為可能，從而改善了臨床決策和患者預後。此外，在分散的醫療機構中，就地檢驗在傳染病篩檢中的應用日益廣泛，這為診斷提供了便利和快速的途徑，尤其是在資源匱乏的地區，從而顯著促進了市場擴張。

市場限制

儘管感染疾病體外診斷市場預計將迎來可觀的成長，但它仍面臨著許多挑戰，包括嚴格的法規結構、複雜的核准流程以及某些地區報銷額度有限。各國監管要求的差異化不僅阻礙了其全球市場滲透，也增加了製造商的開發時間和成本。此外，先進的分子診斷系統和檢測方法價格昂貴，這可能會限制其普及，尤其是在預算限制影響醫療保健成本的中低收入國家。此外，對於檢測準確性、假陽性或假陰性結果以及分散環境下的品管的擔憂，也對市場參與企業構成持續挑戰，因為他們需要努力保持診斷的可靠性和臨床信心。

市場機會

感染疾病體外診斷市場在技術創新、全球衛生重點和不斷發展的診斷需求的推動下，提供了巨大的成長機會。雲端基礎的數據管理和人工智慧主導的診斷演算法等數位健康工具的整合，提高了診斷準確性，並實現了遠端分析，從而支援疾病監測和疫情追蹤。此外，對新型生物標記、快速診斷檢測和綜合檢測試劑盒研發的持續投入，將拓寬市場範圍，並滿足臨床上尚未滿足的需求。個人化醫療的轉變、公私合營的加強以及對新興感染疾病防範的重視，為市場公司開發創新解決方案並增強其在瞬息萬變的感染疾病診斷領域的市場影響創造了途徑。

本報告研究了全球感染疾病體外診斷市場，並對市場動態進行了詳細分析，包括成長動力、趨勢、機會和挑戰。

目錄

第1章執行摘要

第2章 市場概述

  • 市場範圍和定義
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
    • 任務
    • 主要趨勢
  • 宏觀經濟因素
    • 全球產業展望
    • 全球GDP成長前景
  • COVID-19影響分析
  • 預測因子－相關性和影響力

第3章 增值考慮

  • 監管格局
  • 產品採用分析
  • 價值鏈分析
  • 重大交易及合併
  • PESTLE分析
  • 波特五力分析

第4章 全球感染疾病體外診斷市場展望

  • 主要亮點
    • 市場規模及年成長
    • 絕對的商機
  • 市場規模分析及預測
    • 市場規模表現分析（2019-2024）
    • 當前市場規模分析與預測（2025-2032）
  • 全球感染疾病體外診斷市場展望（依產品類型）
    • 簡介/主要發現
    • 按產品類型分類的歷史市場規模分析（2019-2024）
    • 按產品類型分類的當前市場規模分析和預測（2025-2032）
      • 裝置
      • 試劑
      • 軟體、服務
    • 按產品類型進行市場吸引力分析
  • 全球感染疾病體外診斷市場展望：技術
    • 簡介/主要發現
    • 依技術分類的市場規模績效分析（2019-2024）
    • 目前市場規模分析及技術預測（2025-2032）
      • 免疫測量
      • 分子診斷
      • 微生物學
      • 其他
    • 市場吸引力分析：技術
  • 全球感染疾病體外診斷市場展望：應用
    • 簡介/主要發現
    • 歷史市場規模分析：按應用（2019-2024）
    • 目前市場規模分析及應用預測（2025-2032）
      • MRSA
      • 困難梭狀芽孢桿菌
      • 呼吸道病毒
      • 結核病、抗藥性結核病
      • 淋病
      • HPV
      • HIV
      • C型肝炎
      • B型肝炎
      • COVID-19
      • 其他
    • 市場吸引力分析：應用
  • 全球感染疾病體外診斷市場展望：最終用戶
    • 簡介/主要發現
    • 按最終用戶分類的市場規模績效分析（2019-2024 年）
    • 目前市場規模分析及最終用戶預測（2025-2032）
      • 照護現場
      • 中央考場
      • 其他
    • 市場吸引力分析：最終用戶

5. 全球感染疾病體外診斷市場（按地區）展望

  • 主要亮點
  • 市場規模績效分析：按地區（2019-2024）
  • 目前市場規模分析及各地區預測（2025-2032）
    • 北美洲
    • 歐洲
    • 東亞
    • 南亞和大洋洲
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力分析：地區

6. 北美感染疾病體外診斷市場展望

7. 歐洲感染疾病體外診斷市場展望

第8章東亞感染疾病體外診斷市場展望

9.南亞及大洋洲感染疾病體外診斷市場展望

10. 拉丁美洲感染疾病體外診斷市場展望

第11章中東和非洲感染疾病體外診斷市場展望

第12章競爭格局

  • 市場佔有率分析（2025年）
  • 市場結構
    • 競爭強度圖：按市場
    • 競爭儀錶板
  • 公司簡介（詳情－概述、財務狀況、策略、最新發展）
    • QIAGEN
    • Becton, Dickinson and Company
    • bioMerieux SA
    • F. Hoffmann-La Roche, Ltd.
    • Hologic, Inc. (Gen Probe)
    • Abbott
    • Quidel Corporation
    • Siemens Healthineers AG
    • Bio-Rad Laboratories, Inc.
    • Danaher
    • OraSure Technologies, Inc.
    • 其他

第13章 附錄

簡介目錄
Product Code: PMRREP33205

Persistence Market Research has recently released a comprehensive report on the worldwide market for infectious disease in-vitro diagnostics (IVD). The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global infectious disease IVD market from 2025 to 2032.

Key Insights:

  • Infectious Disease IVD Market Size (2025E): USD 46.6 Billion
  • Projected Market Value (2032F): USD 64.1 Billion
  • Global Market Growth Rate (CAGR 2025 to 2032): 4.7%

Infectious Disease In-vitro Diagnostics Market - Report Scope:

Infectious disease in-vitro diagnostics play a crucial role in the rapid and accurate detection of pathogens responsible for infections such as HIV, hepatitis, influenza, tuberculosis, and emerging viral threats like SARS-CoV-2. These diagnostics encompass molecular assays, immunoassays, and point-of-care testing technologies, enabling early diagnosis, guiding treatment decisions, and facilitating infection control efforts. The infectious disease IVD market caters to hospitals, clinical laboratories, diagnostic centers, and point-of-care settings, offering a diverse array of test kits, reagents, instruments, and software solutions. Market growth is driven by the rising prevalence of infectious diseases, increased demand for rapid and accurate testing, and technological advancements in diagnostic platforms, improving sensitivity, specificity, and turnaround times.

Market Growth Drivers:

The global infectious disease IVD market is propelled by several key factors, including the growing incidence of infectious diseases worldwide and heightened awareness of early detection and disease management. The increasing burden of antibiotic-resistant infections, the need for precise diagnostics in outbreak scenarios, and robust government initiatives supporting infectious disease surveillance and screening further accelerate market growth. Technological progress in molecular diagnostics, such as next-generation sequencing and multiplex PCR, enables simultaneous detection of multiple pathogens, enhancing clinical decision-making and patient outcomes. Moreover, the expanding use of point-of-care tests for infectious disease screening in decentralized healthcare settings contributes significantly to market expansion, offering convenience and faster diagnosis, especially in resource-limited regions.

Market Restraints:

Despite promising growth prospects, the infectious disease IVD market faces challenges related to stringent regulatory frameworks, complex approval processes, and reimbursement limitations in certain regions. Variations in regulatory requirements across countries create barriers for global market penetration and increase development timelines and costs for manufacturers. Additionally, the high cost of advanced molecular diagnostic systems and tests can restrict adoption, particularly in low- and middle-income countries where budget constraints affect healthcare spending. Moreover, concerns around test accuracy, false-positive or false-negative results, and quality control in decentralized settings pose ongoing challenges for market players striving to maintain diagnostic reliability and clinical trust.

Market Opportunities:

The infectious disease IVD market presents significant growth opportunities driven by technological innovations, global health priorities, and evolving diagnostic needs. The integration of digital health tools, such as cloud-based data management and artificial intelligence-driven diagnostic algorithms, improves diagnostic accuracy, enables remote analysis, and supports disease surveillance and outbreak tracking. Furthermore, rising investment in research and development for novel biomarkers, rapid diagnostic tests, and syndromic testing panels expands the market scope and addresses unmet clinical needs. The shift toward personalized medicine, increased public-private collaborations, and growing emphasis on preparedness for emerging infectious diseases create avenues for market players to develop innovative solutions and strengthen market presence in the dynamic infectious disease diagnostics landscape.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the infectious disease IVD market globally?
  • Which test types and applications are driving the adoption of infectious disease diagnostics across various healthcare settings?
  • How are technological advancements reshaping the competitive landscape of the infectious disease IVD market?
  • Who are the key players contributing to the infectious disease IVD market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global infectious disease IVD market?

Competitive Intelligence and Business Strategy:

These companies invest in R&D to develop high-sensitivity molecular assays, multiplexed platforms, and rapid point-of-care diagnostics, addressing diverse infectious disease testing needs. Partnerships with healthcare providers, governments, and international health organizations facilitate access to markets, especially during public health emergencies. Moreover, emphasis on automation, integration of digital solutions, and adherence to regulatory standards enables market leaders to deliver reliable, scalable, and cost-effective diagnostic solutions. Continuous efforts in clinical research, assay validation, and global distribution networks further consolidate the competitive landscape in the rapidly evolving infectious disease IVD market.

Key Companies Profiled:

  • QIAGEN
  • Becton, Dickinson and Company
  • bioMerieux SA
  • F. Hoffmann-La Roche, Ltd.
  • Hologic, Inc. (Gen Probe)
  • Abbott
  • Quidel Corporation
  • Siemens Healthineers AG
  • Bio-Rad Laboratories, Inc.
  • Danaher
  • OraSure Technologies, Inc.

Infectious Disease IVD Market Research Segmentation:

The infectious disease IVD market encompasses a diverse range of products, technologies, applications, and end-user segments, addressing various pathogens and patient populations.

By Product Type

  • Instruments
  • Reagents
  • Software and Services

By Technology

  • Immunoassay
  • Molecular Diagnostics
  • Microbiology
  • Others

By Application

  • MRSA
  • Clostridium Difficile
  • Respiratory Virus
  • TB and Drug-resistant TB
  • Gonorrhea
  • HPV
  • HIV
  • Hepatitis C
  • Hepatitis B
  • COVID-19
  • Others

By End User

  • Point-of-care
  • Central Laboratories
  • Others

By Region

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Infectious Disease In-vitro Diagnostics Market Snapshot, 2025 and 2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Regulatory Landscape
  • 3.2. Product Adoption Analysis
  • 3.3. Value Chain Analysis
  • 3.4. Key Deals and Mergers
  • 3.5. PESTLE Analysis
  • 3.6. Porter's Five Force Analysis

4. Global Infectious Disease In-vitro Diagnostics Market Outlook:

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
  • 4.3. Global Infectious Disease In-vitro Diagnostics Market Outlook: Product Type
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Product Type, 2019-2024
    • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
      • 4.3.3.1. Instruments
      • 4.3.3.2. Reagents
      • 4.3.3.3. Software and Services
    • 4.3.4. Market Attractiveness Analysis: Product Type
  • 4.4. Global Infectious Disease In-vitro Diagnostics Market Outlook: Technology
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Bn) Analysis, By Technology, 2019-2024
    • 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
      • 4.4.3.1. Immunoassay
      • 4.4.3.2. Molecular Diagnostics
      • 4.4.3.3. Microbiology
      • 4.4.3.4. Others
    • 4.4.4. Market Attractiveness Analysis: Technology
  • 4.5. Global Infectious Disease In-vitro Diagnostics Market Outlook: Application
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Application, 2019-2024
    • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
      • 4.5.3.1. MRSA
      • 4.5.3.2. Clostridium Difficile
      • 4.5.3.3. Respiratory Virus
      • 4.5.3.4. TB and Drug-resistant TB
      • 4.5.3.5. Gonorrhea
      • 4.5.3.6. HPV
      • 4.5.3.7. HIV
      • 4.5.3.8. Hepatitis C
      • 4.5.3.9. Hepatitis B
      • 4.5.3.10. COVID-19
      • 4.5.3.11. Others
    • 4.5.4. Market Attractiveness Analysis: Application
  • 4.6. Global Infectious Disease In-vitro Diagnostics Market Outlook: End User
    • 4.6.1. Introduction / Key Findings
    • 4.6.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019-2024
    • 4.6.3. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
      • 4.6.3.1. Point-of-care
      • 4.6.3.2. Central Laboratories
      • 4.6.3.3. Others
    • 4.6.4. Market Attractiveness Analysis: End User

5. Global Infectious Disease In-vitro Diagnostics Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Infectious Disease In-vitro Diagnostics Market Outlook:

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Product Type
    • 6.2.3. By Technology
    • 6.2.4. By Application
    • 6.2.5. By End User
  • 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
    • 6.4.1. Instruments
    • 6.4.2. Reagents
    • 6.4.3. Software and Services
  • 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 6.5.1. Immunoassay
    • 6.5.2. Molecular Diagnostics
    • 6.5.3. Microbiology
    • 6.5.4. Others
  • 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 6.6.1. MRSA
    • 6.6.2. Clostridium Difficile
    • 6.6.3. Respiratory Virus
    • 6.6.4. TB and Drug-resistant TB
    • 6.6.5. Gonorrhea
    • 6.6.6. HPV
    • 6.6.7. HIV
    • 6.6.8. Hepatitis C
    • 6.6.9. Hepatitis B
    • 6.6.10. COVID-19
    • 6.6.11. Others
  • 6.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 6.7.1. Point-of-care
    • 6.7.2. Central Laboratories
    • 6.7.3. Others
  • 6.8. Market Attractiveness Analysis

7. Europe Infectious Disease In-vitro Diagnostics Market Outlook:

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Product Type
    • 7.2.3. By Technology
    • 7.2.4. By Application
    • 7.2.5. By End User
  • 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Rest of Europe
  • 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
    • 7.4.1. Instruments
    • 7.4.2. Reagents
    • 7.4.3. Software and Services
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 7.5.1. Immunoassay
    • 7.5.2. Molecular Diagnostics
    • 7.5.3. Microbiology
    • 7.5.4. Others
  • 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 7.6.1. MRSA
    • 7.6.2. Clostridium Difficile
    • 7.6.3. Respiratory Virus
    • 7.6.4. TB and Drug-resistant TB
    • 7.6.5. Gonorrhea
    • 7.6.6. HPV
    • 7.6.7. HIV
    • 7.6.8. Hepatitis C
    • 7.6.9. Hepatitis B
    • 7.6.10. COVID-19
    • 7.6.11. Others
  • 7.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 7.7.1. Point-of-care
    • 7.7.2. Central Laboratories
    • 7.7.3. Others
  • 7.8. Market Attractiveness Analysis

8. East Asia Infectious Disease In-vitro Diagnostics Market Outlook:

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Product Type
    • 8.2.3. By Technology
    • 8.2.4. By Application
    • 8.2.5. By End User
  • 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
    • 8.4.1. Instruments
    • 8.4.2. Reagents
    • 8.4.3. Software and Services
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 8.5.1. Immunoassay
    • 8.5.2. Molecular Diagnostics
    • 8.5.3. Microbiology
    • 8.5.4. Others
  • 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 8.6.1. MRSA
    • 8.6.2. Clostridium Difficile
    • 8.6.3. Respiratory Virus
    • 8.6.4. TB and Drug-resistant TB
    • 8.6.5. Gonorrhea
    • 8.6.6. HPV
    • 8.6.7. HIV
    • 8.6.8. Hepatitis C
    • 8.6.9. Hepatitis B
    • 8.6.10. COVID-19
    • 8.6.11. Others
  • 8.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 8.7.1. Point-of-care
    • 8.7.2. Central Laboratories
    • 8.7.3. Others
  • 8.8. Market Attractiveness Analysis

9. South Asia & Oceania Infectious Disease In-vitro Diagnostics Market Outlook:

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Product Type
    • 9.2.3. By Technology
    • 9.2.4. By Application
    • 9.2.5. By End User
  • 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
    • 9.4.1. Instruments
    • 9.4.2. Reagents
    • 9.4.3. Software and Services
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 9.5.1. Immunoassay
    • 9.5.2. Molecular Diagnostics
    • 9.5.3. Microbiology
    • 9.5.4. Others
  • 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 9.6.1. MRSA
    • 9.6.2. Clostridium Difficile
    • 9.6.3. Respiratory Virus
    • 9.6.4. TB and Drug-resistant TB
    • 9.6.5. Gonorrhea
    • 9.6.6. HPV
    • 9.6.7. HIV
    • 9.6.8. Hepatitis C
    • 9.6.9. Hepatitis B
    • 9.6.10. COVID-19
    • 9.6.11. Others
  • 9.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 9.7.1. Point-of-care
    • 9.7.2. Central Laboratories
    • 9.7.3. Others
  • 9.8. Market Attractiveness Analysis

10. Latin America Infectious Disease In-vitro Diagnostics Market Outlook:

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Product Type
    • 10.2.3. By Technology
    • 10.2.4. By Application
    • 10.2.5. By End User
  • 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
    • 10.4.1. Instruments
    • 10.4.2. Reagents
    • 10.4.3. Software and Services
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 10.5.1. Immunoassay
    • 10.5.2. Molecular Diagnostics
    • 10.5.3. Microbiology
    • 10.5.4. Others
  • 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 10.6.1. MRSA
    • 10.6.2. Clostridium Difficile
    • 10.6.3. Respiratory Virus
    • 10.6.4. TB and Drug-resistant TB
    • 10.6.5. Gonorrhea
    • 10.6.6. HPV
    • 10.6.7. HIV
    • 10.6.8. Hepatitis C
    • 10.6.9. Hepatitis B
    • 10.6.10. COVID-19
    • 10.6.11. Others
  • 10.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 10.7.1. Point-of-care
    • 10.7.2. Central Laboratories
    • 10.7.3. Others
  • 10.8. Market Attractiveness Analysis

11. Middle East & Africa Infectious Disease In-vitro Diagnostics Market Outlook:

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Product Type
    • 11.2.3. By Technology
    • 11.2.4. By Application
    • 11.2.5. By End User
  • 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
    • 11.4.1. Instruments
    • 11.4.2. Reagents
    • 11.4.3. Software and Services
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 11.5.1. Immunoassay
    • 11.5.2. Molecular Diagnostics
    • 11.5.3. Microbiology
    • 11.5.4. Others
  • 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 11.6.1. MRSA
    • 11.6.2. Clostridium Difficile
    • 11.6.3. Respiratory Virus
    • 11.6.4. TB and Drug-resistant TB
    • 11.6.5. Gonorrhea
    • 11.6.6. HPV
    • 11.6.7. HIV
    • 11.6.8. Hepatitis C
    • 11.6.9. Hepatitis B
    • 11.6.10. COVID-19
    • 11.6.11. Others
  • 11.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 11.7.1. Point-of-care
    • 11.7.2. Central Laboratories
    • 11.7.3. Others
  • 11.8. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. QIAGEN
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Becton, Dickinson and Company
    • 12.3.3. bioMerieux SA
    • 12.3.4. F. Hoffmann-La Roche, Ltd.
    • 12.3.5. Hologic, Inc. (Gen Probe)
    • 12.3.6. Abbott
    • 12.3.7. Quidel Corporation
    • 12.3.8. Siemens Healthineers AG
    • 12.3.9. Bio-Rad Laboratories, Inc.
    • 12.3.10. Danaher
    • 12.3.11. OraSure Technologies, Inc.
    • 12.3.12. Others

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations